tyrosine kinase inhibitorGISTmelanomamastocytosisThe history of KIT tyrosine kinase receptor research and clinical investigation is one of the most seminal in oncology. This still evolving story illustrates the intrinsic relationship between gene mutation, protein structure/function, and small molecule ...
[6] Zhang Y, Huang Z. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review. Front Pharmacol. 2023 ...
[9].Smith B D, Kaufman M D, Lu W P, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants[J]. Cancer cell, 2019, 35(5): 738-751. e9.[10].Fletcher J A. KIT oncogenic mutations: biologic...
[4] César Serrano, Suzanne George, Jonathan A Fletcher, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 ...
PLX647详细介绍：PLX647参考文献：[1]. Zhang C, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94.[2]. Louvet C, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic...
Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–32. CASPubMedGoogle Scholar Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: ...
Metabolism inhibitor Age-standardized incidence rates, by age group and overall, were ascertained.The medical records showed that 2070 individuals were diagnosed with at least one basal cell carcinoma (BCC), 1364 with squamous cell carcinoma (SCC), and 258 with melanoma (MM). Rates per 100,000...
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32(IF:16.562). [2] Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 ...
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the...
[9].Smith B D, Kaufman M D, Lu W P, et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants[J]. Cancer cell, 2019, 35(5...